The primary goal of the CETR Administrative Core (Core A) is to promote success for all CETR programs including research programs and cores, supplemental research projects, financial monitoring and oversight, compliance and regulatory activities, biosafety and security issues, for all personnel, materials, data and facilities associated with CCTRHIB programs. The Core will work closely with the Scientific Advisory Board to assure that excellent progress is made on all projects, and that innovative supplemental projects are being funded. The Administrative Core is ultimately responsible for ensuring that the mission of this CETR for novel vaccine technology platform for high medical need infectious is met. Under Dr. Jenny Ting, Program Director and Dr. Barbara Vilen, Associate Director, the Administrative Core supports the scientific and translational goals as follows: (1) Execute day-to-day operations and management, including monitoring of expenditures, addressing grant management issues as well as unexpected issues that arise. (2) Managing, coordinating, and supervising Scientific Projects 1-3 and Cores B-D. (3) Coordinate the review activities ofthe advisory committee, both reviews of Projects and Cores and reviews of supplemental applications. (4) Oversee activities of the research programs, core activities, supplemental research projects to assure proper compliance and regulatory activities, biosafety and security issues for all personnel, materials, data publication and resource sharing, and technology transfer/intellectual properties necessary for product development associated with Center programs.

Public Health Relevance

The Administrative Core is ultimately responsible for ensuring the successful completion of the Center's mission to advance medical countermeasures to Emerging and Re-emerging Infectious Diseases. The Scientific Administrators, the Administrative Staff and Regulatory personnel will work together toward that goal. The Administrative Core is ultimately responsible for ensuring the successful completion of the Center's mission to advance medical countermeasures to Emerging and Re-emerging Infectious Diseases. The Scientific Administrators, the Administrative Staff and Regulatory personnel will work together toward that goal.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109784-01
Application #
8657215
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Metz, Stefan W; Gallichotte, Emily N; Brackbill, Alex et al. (2017) In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers. Sci Rep 7:4524
Junkins, Robert D; Gallovic, Matthew D; Johnson, Brandon M et al. (2017) A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. J Control Release 270:1-13
Cheng, Liang; Zhang, Zheng; Li, Guangming et al. (2017) Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system. Vaccine 35:6143-6153
Kai, Marc P; Brighton, Hailey E; Fromen, Catherine A et al. (2016) Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle Clearance. ACS Nano 10:861-70
DeSimone, Joseph M (2016) Co-opting Moore's law: Therapeutics, vaccines and interfacially active particles manufactured via PRINT®. J Control Release 240:541-543
Metz, Stefan W; Tian, Shaomin; Hoekstra, Gabriel et al. (2016) Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses. PLoS Negl Trop Dis 10:e0005071
Fromen, Catherine A; Rahhal, Tojan B; Robbins, Gregory R et al. (2016) Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells. Nanomedicine 12:677-687
Callaway, Justin B; Smith, Scott A; Widman, Douglas G et al. (2015) Source and Purity of Dengue-Viral Preparations Impact Requirement for Enhancing Antibody to Induce Elevated IL-1? Secretion: A Primary Human Monocyte Model. PLoS One 10:e0136708
Callaway, Justin B; Smith, Scott A; McKinnon, Karen P et al. (2015) Spleen Tyrosine Kinase (Syk) Mediates IL-1? Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection. J Biol Chem 290:17306-20
Robbins, Gregory R; Roberts, Reid A; Guo, Haitao et al. (2015) Analysis of human innate immune responses to PRINT fabricated nanoparticles with cross validation using a humanized mouse model. Nanomedicine 11:589-99

Showing the most recent 10 out of 14 publications